Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including administering Medicaid benefits, which were affected by a federal pause on eligibility reviews during COVID-19 [3]. - Following the end of the pause in 2023, states resumed redetermining Medicaid eligibility, which led to significant increases in acuity and utilization among Elevance's Medicaid members [5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate [4]. - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, causing a further stock decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for alleged violations of federal securities laws, specifically regarding misleading statements about the acuity and utilization of its Medicaid members during a specific period [1]. Group 1: Lawsuit Details - The lawsuit pertains to shareholders who purchased Elevance's securities between April 18, 2024, and October 16, 2024 [1]. - The complaint claims that Elevance misrepresented the impact of Medicaid redeterminations, suggesting that members removed from Medicaid were healthier than those who remained eligible [1]. - It is alleged that the changes in utilization were not accurately reflected in the company's negotiations with states or in its financial guidance to investors [1]. Group 2: Investor Participation - Shareholders who experienced losses are encouraged to contact the DJS Law Group to participate in the class action [2]. Group 3: DJS Law Group Profile - DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [3]. - The firm represents some of the largest hedge funds and alternative asset managers globally, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members in the litigation [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors, including over $438 million in 2019 [3]. Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its impact on cost trends [4]. - Defendants assured investors that premium rates negotiated with states were sufficient to manage the risk and costs associated with Medicaid patients, which was later revealed to be misleading [4]. - The true impact of the redetermination process led to a significant rise in acuity and utilization of Medicaid members, contrary to Elevance's financial guidance for 2024 [4].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, titled Miller v. Elevance Health, Inc., et al., No. 25-cv-0092, and investors have until July 11, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock [2]. Group 2: Medicaid Management Issues - Elevance provides health insurance plans, including Medicaid benefits, and the federal government paused Medicaid eligibility reviews during COVID-19, which resumed in 2023 [3]. - During this period, Elevance claimed to be monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate for the risk profiles of Medicaid patients [4]. Group 3: Financial Impact and Stock Performance - The redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. - Following a July 17, 2024 announcement regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, resulting in a stock price decline of $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. common stock is from April 18, 2024, to October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members in the litigation [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance [4]. - It is claimed that the company assured investors that rising Medicaid expenses were adequately reflected in its guidance, which was not the case [4]. - The true impact of the redetermination process led to a significant rise in the acuity and utilization of Medicaid members, contrary to the company's representations [4].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. The EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. - Elevance had previously claimed to be monitoring cost trends and negotiating sufficient rates for Medicaid patients, which was later alleged to be misleading [4]. Group 3: Stock Performance and Financial Impact - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, resulting in a stock decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - Elevance Health's shares have decreased by 27% over the past year, significantly underperforming the broader market over the last 1, 3, and 5 years [1]. Group 1 - The stock's underperformance is attributed to various reasons that are not detailed in the provided content [1].

Core Viewpoint - Investors in Elevance Health, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its financial guidance and operational costs [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that between April 18, 2024, and October 16, 2024, Elevance Health failed to disclose critical information to investors, including the fact that sicker patients with higher acuity remained on Medicaid after redetermination, leading to increased per-patient costs [3]. - It is claimed that the rise in costs was not adequately reflected in Elevance's rate negotiations with states or in its financial guidance for 2024, resulting in materially misleading statements about the company's business and prospects [3]. Participation Information - Investors who suffered losses in Elevance Health are encouraged to contact the Law Offices of Howard G. Smith before July 11, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email, phone, or the law firm's website for more information regarding their legal rights and the class action [4][5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of false and misleading statements regarding Medicaid cost trends and earnings guidance, which led to significant stock price declines [3][5][6]. Group 1: Allegations and Financial Impact - The complaint alleges that Elevance and its executives violated federal securities laws by making false statements about monitoring cost trends and the adequacy of premium rates for Medicaid patients [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, or 5.8% [6]. - On October 17, 2024, Elevance reported third-quarter earnings that missed consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further stock price decline of $52.61 per share, or 10.6% [7][8]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses in Elevance between April 18, 2024, and October 16, 2024, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][3]. - There is a deadline of July 11, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Elevance [3]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9].